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ABSTRACT
Maldonado-Soto AR, Oakley DH, Wichterle H, Stein J, Doetsch FK, Henderson CE:
Stem cel ls in the nervous system. Am J Phys Med Rehabi l
2014;93(Suppl):S132YS144.
Given their capacity to regenerate cells lost through injury or disease, stem cells
offer new vistas into possible treatments for degenerative diseases and their un-
derlying causes. As such, stem cell biology is emerging as a driving force behind
many studies in regenerative medicine. This review focuses on the current un-
derstanding of the applications of stem cells in treating ailments of the human brain,
with an emphasis on neurodegenerative diseases. Two types of neural stem cells
are discussed: endogenous neural stem cells residing within the adult brain and
pluripotent stem cells capable of forming neural cells in culture. Endogenous neu-
ral stem cells give rise to neurons throughout life, but they are restricted to spe-
cialized regions in the brain. Elucidating the molecular mechanisms regulating these
cells is key in determining their therapeutic potential as well as finding mechanisms
to activate dormant stem cells outside these specialized microdomains. In parallel,
patient-derived stem cells can be used to generate neural cells in culture, providing
new tools for disease modeling, drug testing, and cell-based therapies. Turning
these technologies into viable treatments will require the integration of basic sci-
ence with clinical skills in rehabilitation.
Key Words: Stem Cells, Regenerative Medicine, Amyotrophic Lateral Sclerosis,
Parkinson Disease
OVERVIEW
Recent developments in stem cell biology have contributed significantly to
the understanding of brain development and maintenance. In this overview, the
ways in which they also show promise for rehabilitation and regenerative med-
icine are summarized.
This review focuses on two distinct populations of stem cells: endogenous
neural stem cells (NSCs) in the adult brain and pluripotent stem cell lines that
can be differentiated into neural cells in culture. Dysfunction of endogenous
stem cells or their nicheVthe specialized environment in which they growVmay
underlie aspects of brain disease and aging. On the other hand, the ability to
create new neurons and glia from patient-derived stem cells offers new hope for
disease modeling, drug testing, and cell-based therapy. In order for these insights
to generate concrete advances in regenerative medicine, a partnership must be
built between those performing rigorous mechanistic biology, others using
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human and animal models for preclinical studies,
and physicians-scientists with a deep knowledge of
patients’ needs and relevant outcome measures.
During development, pluripotent embryonic
stem cells (ESCs) give rise to all brain cell types,
often via multipotent precursor populations of more
limited potential. Although, in the adult brain, gen-
eration of new cells is reduced compared with many
other tissues, adult NSCs persist in two main areas:
the ventricular-subventricular zone (V-SVZ), where
NSCs give rise to olfactory neurons, and the hippo-
campus, where new neurons involved in cogni-
tive processes are generated. In both regions, the
stem cells that give rise to neurons are specialized
populations of astrocytes that maintain close in-
teractions with the brain vasculature and can be
activated by behavioral and pharmacologic stimuli.
Given the ability of NSCs to migrate to sites of in-
jury, amplification of their capacity to generate neu-
rons has therapeutic potential. The expected benefits
of modulating endogenous NSCs would be even
more widespread if astrocytes from other brain re-
gions could be induced to adopt stem cell properties.
Much research is therefore focused on the mecha-
nisms underlying NSC differentiation and on the
cellular andmolecular characteristics of their niche.
To everyone’s knowledge, no drug has ever
been tested for its effects on sick human neurons
before the initiation of clinical trials for neuro-
degenerative diseases such as Alzheimer disease,
Parkinson disease (PD), or amyotrophic lateral scle-
rosis (ALS). The recent technology for creating in-
duced pluripotent stem cells (iPSCs) from patient
tissues has allowed the possibility to directly evaluate
emerging drugs in cultured human disease-specific
cells. It is now possible to generate multiple classes
of neurons and glia from human ESCs (hESCs) or
patient-derived iPSCs and to establish Bdisease in
the culture dish[ models that shed light on human
disease mechanisms and allow for drug testing in
vitro. Moreover, although replacement of neuronal
circuits remains a distant goal, the grafting of stem
cellYderived support cells to slow neuronal degen-
eration in specific regions of the brain or spinal cord
has shown promise in animal models and is being
tested in early human trials.
Despite its promise, NSC biology still needs
to cross several hurdles before its full clinical im-
pact is realized. Potential implications of NSC dis-
coveries in rehabilitation medicine for the coming
decades may include improved treatments for neu-
rodegenerative disease and stroke, among others.
Taken together with the very active stem cell and
bioengineering research being performed on the
bone, connective tissue, and muscle, these avenues
may lead to a radical change in the approach to
patient rehabilitation and provide hope for signifi-
cant clinical benefit.
STEM CELL BASICS
Stem cells have two essential properties: (1)
They divide to give rise to another stem cell (self-
renewal), and (2) they undergo differentiation to
form diverse cell types (Fig. 1A). Stem cells play a
central role both during development and in the
adult. During embryogenesis, they give rise to all
the different cell types that compose the human
body. In addition, many (but not all) adult tissues
retain pools of endogenous stem cells charged with
replenishing cells lost through turnover (homeo-
stasis), as well as regenerating the tissue after lesions.
The property of self-renewal ensures that the stem
cell pool is maintained throughout life. Stem cells
often give rise to differentiated progeny via short-
lived rapidly dividing intermediate progenitors, thereby
increasing the output of cells derived from a single
stem cell (Fig. 1A). Many adult stem cells are still
capable of giving rise to different cell types albeit to
a lesser extent than their embryonic counterpart.1
Stem cells reside within specialized cellular
environments, called niches, which modulate many
aspects of their biology (Fig. 1B). Elements within
the niche provide positional cues important in de-
termining which daughter cell retains stem cell
identity and which daughter cell progresses down
the lineage to form more differentiated progeny. In
addition, cells within the niche provide factors im-
portant for the survival of the stem cells and the
differentiation of their progeny. Properties of both
stem cells and their niche vary during development
and according to the tissue in which they are found.
Moreover, both are affected in human disease and
aging. As one example, dysregulation of either stem
cells or their niche can lead to cancer.2Y5 In the
following sections, stem cells and their niche in the
adult nervous system, how they are affected in dis-
ease, and how they might contribute to central
nervous system (CNS) regeneration are reviewed.
Endogenous Adult NSCs and Their Niche
The CNS is composed of neurons, astrocytes,
and oligodendrocytes as well as other nonneural
cell types. Neurons, the main effector cells of the
CNS, process the information entering and leaving
the CNS. Astrocytes, a very diverse class of cells, are
the main support cells of the CNS, with functions
that range from regulating which molecules in the
blood enter the brain to phagocytosing cellular
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debris in the parenchyma and maintaining brain
homeostasis.6,7 Oligodendrocytes form myelinating
sheaths along axons, allowing the rapid propagation
of action potentials by neurons. During embryonic
brain development, all three of these cell types arise
from the same pool of stem cells: radial glial cells.8
Most neurogenesis ends around birth. However,
it is now clear that new neurons are continuously
generated by stem cells in restricted brain regions of
the adult mammalian brain throughout life. Adult
neurogenesis occurs in two regions, the V-SVZ of
the lateral ventricles, which generates olfactory bulb
neurons, and the subgranular zone (SGZ) in the
hippocampal formation9 (Fig. 2A). Some oligoden-
drocytes are also formed in both regions. Strikingly,
in both adult neurogenic niches, the NSCs are spe-
cialized astrocytes, raising the question of whether
astrocytes in other brain regions might also retain
latent stem cell capacity.
Most of the knowledge about adult neuro-
genesis comes from studies in rodents. The V-SVZ
extends along the length of the lateral ventricles
and is the largest germinal region in the adult
brain. Quiescent NSCs in the V-SVZ become acti-
vated to divide and generate intermediate transit-
amplifying progenitors, which in turn give rise to
new neurons that migrate to the olfactory bulb10,11
(Figs. 2A, B). NSCs in the V-SVZ have a polarized
morphology and span different compartments of
the stem cell niche.12 NSCs extend a thin process
between ependymal cells, which line the ventricles,
and are thereby continuously bathed by cerebro-
spinal fluid13Y15 (Fig. 2B). On the basal side, NSCs
extend a long process to contact blood vessels
within the V-SVZ niche. In recent years, the blood
vessels in the V-SVZ have emerged as an impor-
tant proliferative compartment of the niche.16Y18
Notably, the vasculature in this region of the brain
has unique features. Dividing stem cells and their
transit-amplifying progeny frequently contact blood
vessels directly at specialized sites lacking astrocyte
end-feet and pericyte coverage.16 Moreover, signals
in the blood are able to directly access the V-SVZ.16
Thus, stem cells in this region are uniquely exposed
to both contact-mediated and diffusible signals from
the vasculature as well as systemic signals in the
circulation. Interestingly, long distance and local neu-
rons also innervate the V-SVZ, suggesting a role for
circuit regulation within the niche.
In the SGZ, NSCs also extend a radial process
and generate new neurons via a short-lived inter-
mediate progenitor (Fig. 2B). The newly generated
neurons travel a short distance into the granule cell
layer, where they integrate into the local circuitry.
FIGURE 1 Stem cells self-renew and give rise to differentiated progeny. A, Stem cells (black) divide to form another
stem cell (self-renewal) and a progenitor cell (light gray). Progenitor cells divide to amplify their
number and, in turn, give rise to more differentiated progeny (white). B, Stem cells reside in specialized
niches, which provide important positional cues and regulatory elements that influence stem cell
behavior. When a stem cell divides, the daughter cell that retains a stem cell identity is kept within
the boundaries of the niche, whereas the other daughter cell loses the constraint on its phenotype.
This second daughter cell now forms undifferentiated progenitors, which in turn give rise to more
differentiated progeny.
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The vasculature is also an important niche com-
partment in the SGZ. However, there are interest-
ing differences. Unlike the V-SVZ, the vasculature is
angiogenic in the SGZ, with neurogenesis occur-
ring near the angiogenic foci.19 The activity of local
interneurons plays an important role in mediating
FIGURE 2 Endogenous adult NSCs and their niche. A, Schema of a sagittal section of an adult mouse brain showing
the V-SVZ adjacent to the lateral ventricles and SGZ of the hippocampal formation. New neurons born
in the V-SVZ migrate a long distance to their final destination in the olfactory bulb (arrow). In contrast,
adult-born neurons in the SGZ integrate locally into the circuitry. B, Schema of cell types and the
anatomy of adult neurogenic niches. The V-SVZ niche (left) is composed of astrocyte NSCs (black), which
contact the ventricular lumen between multiciliated ependymal cells and extend a radial process that
contacts blood vessels. These cells give rise to amplifying progenitors (light gray), which in turn differ-
entiate to migrating immature neurons (white). These immature neurons migrate to the olfactory bulbs,
where they mature into interneurons. NSCs and progenitors often directly contact blood vessels at
specialized sites that lack astrocyte end feet. The SGZ niche (right) is also composed of astrocyte NSCs
(black) in contact with blood vessels, but these cells do not contact the ventricular lumen. SGZ NSCs
also give rise to immature neurons through progenitors, and these neurons travel along the radial
processes of the NSCs to integrate within the local circuitry. Local interneurons regulate SGZ NSCs.
C, Schema showing adult NSC niches in the human brain. Future mechanistic studies on the biology
of both regions will provide important insight into how to harness these endogenous NSCs and exploit
their therapeutic potential. By modulating molecular pathways that regulate adult NSCs, it may
eventually be possible to stimulate astrocytes elsewhere in the brain to become NSCs.
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NSC quiescence in the SGZ20 (Fig. 2B). Impor-
tantly, alterations in natural physiologic states can
have potent effects on ongoing stem cell prolifera-
tion and adult neurogenesis. Exercise, pregnancy,
and enriched environments stimulate different as-
pects of NSC proliferation and survival of newly
generated neurons. In contrast, stress and aging in-
hibit proliferation and neurogenesis.21 As the mo-
lecular underpinnings mediating these effects are
uncovered, it may be feasible to stimulate neuro-
genesis and oligodendrocyte formation.
In adult humans, NSCs are also present through-
out life in both the V-SVZ and the SGZ as special-
ized astrocytes.22 Whereas active neurogenesis occurs
in the SGZ in humans,23 the levels of neurogenesis
in the V-SVZ declines dramatically after infancy.24
Interestingly, infants also possess a second migra-
tory route to the prefrontal cortex not observed
in nonhuman mammals. Thus, in the adult human
V-SVZ, NSCs are largely in a dormant state. How-
ever, as outlined later, they divide under patholo-
gic stimulation. As such, illuminating the pathways
underlying stem cell quiescence and activation in
rodents may shed light on how these stem cells are
recruited upon injury or to form oligodendrocytes
under baseline conditions.
Endogenous NSCs During Disease
and Regeneration
Adult neurogenic niches harbor a pool of en-
dogenous NSCs that could potentially be exploited for
therapeutic purposes. Using fluorescence-activated
cell sorting, adult NSCs can be directly harvested
from tissue samples. Indeed, evidence that adult NSCs
persist into adulthood in humans comes from studies
where these cells have been isolated from surgical
specimens of brain tissue and grown in cell cul-
tures.22,25 Isolating these cells allows for the careful
dissection of their molecular characteristics in vitro,
providing insight into their regulation and poten-
tial for regeneration. In addition, the ability to grow
these cells in isolation allows the elucidation of the
mechanisms required for neurogenesis to success-
fully occur.
Changes to NSCs After Disease and Injury
NSCs react strongly to pathologic conditions
in the adult brain. In the V-SVZ niche, there is in-
creased proliferation after ischemic stroke in the
adjacent striatum or overlying cortex, including in
humans.26Y28 In mouse models of ischemic stroke,
newly formed neuroblasts migrate to the sites of
ischemic lesion and form synaptic connections with
neurons in the vicinity.28 In animal models of
multiple sclerosis, there is an increased influx of
V-SVZYderived cells into sclerotic lesions,29,30 and
there is evidence of this occurring in humans as
well.31,32 Determining whether these mechanisms
contribute to healing, and whether they are con-
served in humans, will be important in the search for
better therapeutic strategies for these and other
conditions.
Neurogenesis in the SGZ is associated with
learning and memory, mood regulation, and pat-
tern separation. Changes in neurogenesis may be
one pathophysiologic cause of various affective dis-
orders.33,34 Moreover, certain psychological states
(i.e., anxiety and stress) decrease the amount of hip-
pocampal neurogenesis. Experimentally decreasing
hippocampal neurogenesis in rodent models leads
to behavioral effects similar to those seen in models
of anxiety.35
Another important NSC-related change is that
both V-SVZ and SGZ show a decrease in neuro-
genesis with aging.36,37 It remains to be determined
whether this is caused by a loss of cells or a shift
to a dormant (nonproliferative) state. In contrast,
SGZ NSCs in humans seem to increase their rate of
neurogenesis during chronic neurodegenerative dis-
eases such as Alzheimer disease.38
Therapeutic Strategies Based on
Endogenous NSCs
The ability of NSCs to generate new neurons in
certain niches provides hope that, if this process
could be amplified and/or extended, it could serve as
the basis for regenerative strategies in both neuro-
vascular and neurodegenerative diseases. Amplifi-
cation of NSCs may already be part of standard
clinical practice. Intriguingly, increased neurogen-
esis in the SGZ has been implicated in the thera-
peutic effects of selective serotonin reuptake inhibitor
antidepressants, potentially explaining the time
needed for these drugs to take full effect.33,34 The
degree to which this can be generalized to human
patients and other antidepressants remains to be
determined. Importantly, physical activity increases
neurogenesis in both V-SVZ and SGZ,21 suggesting
that nonpharmacologic approaches could also be
used to target these cells. More generally, expanding
the relatively limited potential of NSCs to generate
other cell types could be important. Another still
speculative therapeutic possibility is that some of
the molecular mechanisms involved in the differ-
entiation of NSCs could be used to activate astroglial
cells elsewhere in the brain (Fig. 2C). Indeed, after
traumatic brain injuries, glial cells in the vicinity of
the lesion proliferate and form a glial scar. This glial
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scar has been proposed to create a negative environ-
ment for neurogenesis and proper wound healing.
By further understanding the niche elements in the
V-SVZ and SGZ that permit such abundant neuro-
genesis to occur, it might be possible to find ways
to turn the environment in these glial scars, and
elsewhere in the brain, into a more permissive
one. Elucidating this will be a key in understand-
ing the therapeutic potential of these cells and other
astroglial cells in the brain.
Making Neurons From Stem Cells in the
Culture Dish
The preceding sections focused on the pro-
duction of neurons from stem cells in situ and how
this might be modulated in the therapeutic context.
This is a rapidly developing field, but more emphasis
still is being put on the potential uses of neurons
and glia generated from stem cells in the laboratory,
either to model diseases in vitro as a basis for drug
testing or for direct cell replacement strategies.
Human Stem CellYDerived Neurons Open
New Avenues
Both aspects of this approach rely on the abil-
ity to generate neurons from human stem cells,
through methods to be discussed in more detail
later. This possibility is bringing about a sea change
in the approaches to many neurologic and psychi-
atric diseases and, in particular, to neurodegener-
ative diseases. As one example, in patients with ALS,
degeneration and death of cortical and spinal motor
neurons lead to progressive muscle paralysis, often
starting in the distal limbs and progressing to
the respiratory muscles.39 However, the sole Food
and Drug Administration-approved drug for ALS,
riluzole, confers only modest clinical benefit.40 There
is therefore a pressing need for disease-modifying
treatments. One major obstacle to a successful
therapy for ALS is the near-absence of validated
targets, molecular events in the disease pathway
whose inhibition would slow onset or progression.
Genes such as superoxide dismutase 1 whose muta-
tion can lead to ALS may be considered to be vali-
dated targets, but familial forms of the disease
collectively represent only 10% of all cases. Thera-
peutic targets applicable to the 90% of sporadic
cases would likely be genes acting early in the dis-
ease pathway. If such targets could be identified,
they would provide a solid foundation for targeted
drug discovery programs.
Most studies on the mechanisms of ALS have fo-
cused on mouse models expressing disease-triggering
mutant forms of superoxide dismutase 1.41 These
mice develop a disease that strikingly mimics not
only familial but also sporadic ALS, including se-
lective resistance of oculomotor and slow spinal
motor neurons.42 However, even in this model, there
are few validated targets other than the superoxide
dismutase 1 gene itself. Moreover, concerns have
been raised that results obtained in mutant super-
oxide dismutase 1 mice may not translate well to the
clinic. Although this may in part reflect underpow-
ered mouse preclinical studies, there is a need for
human models to discover and validate novel can-
didate disease modifiers. Strikingly, none of the
many drugs that have undergone clinical trials in
ALS were ever first tested on the cells affected in this
disease: human motor neurons. The best strategy
would seem to be to evaluate candidate treatments in
two systems in parallel: human motor neurons from
familial and sporadic patients in vitro and the mouse
neuromuscular system in vivo.
Making Motor Neurons from Pluripotent
Stem Cells
For this reason, the authors and others have
begun to use motor neurons and other cell types
generated from human iPSCs to model ALS in the
culture dish. The first step was to devise protocols
by which stem cells can be coaxed into losing their
stem cell properties and adopting those of differen-
tiated, postmitotic neurons. This was first achieved
using mouse ESCs, by carefully mimicking the step-
wise process in the embryo through which external
factors guide stem cells through a series of interme-
diate stages to become motor neurons43 (Fig. 3). This
process is very robust and generates billions of cells
that are Breal[ motor neurons by many molecular
and functional criteria.
The authors and others subsequently used ad-
aptations of the same protocol to generate motor
neurons from hESCs.44Y46 This approachmade living
human motor neurons widely available for the first
time. However, hESC-derived motor neurons have
at least one significant drawback for disease model-
ing: Existing lines were derived from embryos rep-
resentative of healthy controls. There are essentially
two ways to overcome this. First, it is possible to
introduce into hESCs copies of mutant genes known
to cause familial forms of ALS or other neurodegen-
erative diseases and to study their effect on motor
neuron survival and regeneration. Second, a more
far-reaching change occurred when Yamanaka and
his colleagues demonstrated the possibility of repro-
gramming differentiated cells to iPSCs.47 They showed
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that, after the introduction of 3Y4 stem cell genes
into skin fibroblasts cultured after biopsy, not only
do the cells adopt a stem cell phenotype, they nearly
completely Bforget[ their skin cell origin. iPSCs
from human ALS patients and controls were used to
generate patient-specific motor neurons with high
yield45,48 (Fig. 3). Although some differences be-
tween these and the gold-standard hESCs certainly
exist, they are relatively minor in most cases, and
iPSCs have generated enormous excitement because
of their potential applications in disease modeling
and regenerative therapy. Directed differentiation
of iPSCs provides the first patient-specific access
to living preparations of many tissue types. By cap-
turing patient-specific genetic background, iPSCs
enable modeling of poorly understood complex ge-
netic disorders, creation of humanized disease models
that may be used to study disease modifiers and other
correlations with clinical data, and immunologically
matched tissue for eventual cell-replacement therapy.
Despite these many advantages, the derivation
of iPS lines and their subsequent differentiation
can be a lengthy process. More recently, different
groups have shown that it is possible to take a
shortcut by direct reprogramming skin fibroblasts
or ESCs into motor neurons (Fig. 3). In this case,
it is motor neuron genes, not stem cell genes, that
are introduced as part of the reprogramming pro-
cess.49Y51 This type of approach allows mouse motor
neurons to be generated in as little as 2 days from
ESCs, but both techniques have their advantages
and will likely coexist.
Disease Modeling Using Human
iPSC-Derived Neurons
The past years have seen the development of
a number of hiPSC-based neurodegenerative and
neurologic disease models. The basic Bdisease in the
culture dish[ paradigm of these models involves
producing iPSCs from groups of patients; differen-
tiating them into disease-relevant cell types; and
assessing the derivatives for changes in gene ex-
pression, survival, protein localization/aggregation,
sensitivity to exogenous stressors, or physiologic ac-
tivity. Disease-related phenotypes have been observed
FIGURE 3 Making motor neurons from stem cells. ESCs are generated from early human embryos, whereas
differentiated skin cells can be turned into iPSCs by up-regulating specific stem cell genes. Both ESCs
and iPSCs can be directed to differentiate into motor neurons through a multistep process by culturing
them for weeks in the presence of factors that mimic normal neuronal development (directed differenti-
ation). A more rapid process (days) is the direct reprogramming of ESCs (or fibroblasts, not shown)
into motor neurons directly by forced expression of motor neuron genes.
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in iPS-derived neurons from patients with schizo-
phrenia, Huntington disease, PD, familial dysauto-
nomia, Rett syndrome, spinalmuscular atrophy, and
ALS.52Y57 Mechanistic characterization of such phe-
notypes is nascent but promising. Another critical
feature needed for rigorous analysis is to show that
any Bclinical phenotype[ observed in the culture
dish is truly caused by the disease gene and not by
interindividual differences in genetic background
between the patient and control samples. The best
way of doing this is to Bcorrect[ the mutation in
a given iPSC line so as to create a gene-corrected
(isogenic) control line, which only differs from the
patient-derived line by this single change.58 How-
ever, this has been performed in very few published
studies. Some examples of diseases modeled using
iPSCs will be given later.
Rett Syndrome
iPSCs derived from female patients with Rett
syndrome, another neurodevelopmental disorder,
can be efficiently differentiated to neurons. How-
ever, Rett iPS neurons exhibit decreased synaptic
connectivity, spine density, and soma size as well as
reduced spontaneous action potential firing in cul-
ture.54 These deficits are consistent across multiple
Rett iPSC lines and can be rescued by repletion of
mutant protein or treatment with insulin-like growth
factor-1. However, even in this system, genetic and
epigenetic instabilities have proven to be concerns.59
Schizophrenia
iPS neurons derived from adult-onset schizo-
phrenic patients also display decreased synaptic con-
nectivity, spine density, and soma size in culture but
show no apparent differences in spontaneous action
potential.55 Expression profiling reveals a large num-
ber of differences between schizophrenia neurons
and controls, some of which have been observed in
previous work performed on post-mortem patient
samples. Treatment with Loxapine, but not other
antipsychotic drugs, was able to reverse some pu-
tative schizophrenia iPS disease phenotypes, in-
cluding select expression changes.55
Parkinson Disease
Sensitivity to environmental stressors has also
been observed in disease-specific iPS neurons. Do-
paminergic neurons derived from a single PD patient
were more sensitive to 6-hydroxydopamineYinduced
cell death than those derived from a control iPS or
hES line.57 Although mixed cultures of dopami-
nergic neurons derived from a PD patient were also
more sensitive to the oxidative stressor hydrogen
peroxide, the tyrosine hydroxylase-positive dopa-
minergic neurons themselves were not. More re-
cently, iPS models of PD have been used to address
a potential drawback of such culture systems for
studying late-onset adult diseases. By expressing
progerin, a gene associated with premature aging, it
was possible to enhance the PD-related phenotypes
in the culture model.60
Spinal Muscular Atrophy
Spinal muscular atrophy patients show a char-
acteristic loss of spinal motor neurons. Spinal mus-
cular atrophy iPS-derived motor neurons exhibit
a dearth of nuclear survival motor neuron protein
(SMN) aggregates, a pathologic hallmark of the dis-
ease.52 This effect can be partially rescued by treat-
ment with drugs known to increase SMN in other
tissues. Furthermore, spinal muscular atrophy iPS-
motor neurons (MNs) are less abundant in culture
than control iPS-MNs after 6 wks of differentiation,
despite being present at similar levels 2 wks before
this time point.52 The numbers of motor neurons
can be increased either by genetic correction of the
deficit61 or by blocking apoptosis.62
Amyotrophic Lateral Sclerosis
ALS was the first disease to be modeled using
patient-derived iPSCs.48 Since then, multiple at-
tempts have been made to generate a model of
BALS in the culture dish[ that is clearly relevant to
the human disease. Perhaps, unsurprisingly, for a
late-onset disease such as this, motor neurons from
ALS patients do not show spontaneous degenera-
tion in the few weeks they can be maintained in
culture. Instead, in several cases, iPS-MNs derived
from familial forms of the disease do exhibit some
of the molecular hallmarks of human pathology.56
Motor neurons derived from patients with the most
frequent familial mutation, in C9ORF72, show char-
acteristic accumulations (foci) of mutated RNA.63,64
Even this is not alone sufficient to trigger neuro-
degeneration, and it is necessary to stress the ALS
neurons with high levels of glutamate to observe
exacerbated cell death. This vulnerability can be re-
versed using DNA antisense oligonucleotides tar-
geting the disease gene.63
In addition to artificial aging or exposure to
stressors, another approach to disease modeling is
to more fully recreate the cellular environment of
motor neurons within the spinal cord. Astrocytes
normally provide a supportive niche for motor neu-
rons within the adult CNS. However, in both mouse
and human models, it has been reported that ALS
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astrocytes instead become toxic for motor neurons,
secreting factors that can trigger neuronal death.65Y67
The availability of stem cellYderived motor neurons
and astrocytes,68 in some cases in combination with
astrocytes harvested from post-mortem CNS with
familial or even sporadic forms of the disease,69 has
made it possible to generate coculture systems in
which this toxic nonYcell-autonomous interaction
leads to spontaneous motor neuron degeneration
in the culture dish. The immediate goal will be to
create a fully humanizedmodel of ALS in the culture
dish that shows spontaneous neurodegeneration
using astrocytes of both familial and sporadic ALS
origins (Fig. 4).
The emergence of humanized disease models of
ALS has opened the door to their use for screening
collections of small molecules for neuroprotective
drug candidates. For technical reasons, it is not yet
feasible to perform screening on human models on
a large scale. However, arguably, all candidate disease
treatments should now be evaluated in such sys-
tems, hopefully increasing the predictive value of
preclinical studies.
Cell-Based Therapy in the
Nervous System
In parallel with attempts to slow neurode-
generation using drugs developed with the help of
stem cell models, a future strategy would be to re-
place lost neurons. In reality, this is an extraordi-
narily challenging goal. In a disease such as ALS, it
would be necessary not only to get grafted motor
neurons to establish themselves in the spinal cord
and send out axons to distant target muscles but
also for the new motor neurons to become inte-
grated in the circuits involved in motor control. At
present, this prospect must be considered distant.
Even for the dopaminergic neurons lost focally in
PD patients, no robust technology yet exists to
generate neurons in sufficient quantity and quality,
FIGURE 4 Human ALS in the culture dish. To date, human ALS astrocytes have been shown to be toxic for mouse
ESC-derived motor neurons, as are mouse ALS astrocytes for hESC-derived motor neurons. The ideal
system would be a completely humanized model as depicted here, in which astrocytes (light gray)
are derived from post-mortem brain or ALS ESCs/iPSCs and motor neurons (dark gray) are generated
from ESCs/iPSCs. If human astrocytes lead to spontaneous motor neuron degeneration in this sim-
plified culture system, it should be possible to test drugs for their efficacy in preventing ALS-related
motor neuron cell death as well as study the cellular and molecular mechanisms underpinning
disease progression.
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but this will likely be the neurologic disease where
the first neuronal replacement trials are carried out.
An alternative, parallel approach involves the
development of paracrine therapies. One possibil-
ity, as in models of epilepsy or neuropathic pain, is
to reintroduce local interneurons that can correct
the properties of dysfunctional neural circuits.70,71
Stem cells and their glial derivatives have the po-
tential to serve as local Bfactories[ of growth fac-
tors that support the repair of nearby tissues.72
Thus, placement of stem cells in a damaged brain
may facilitate repair through these paracrine effects,
rather than relying on direct replacement of miss-
ing cells. The cell populations evaluated for this type
of approach range from mesenchymal stem cells to
more targeted glial precursor populations.73 Cells
may be administered either locally, using cutting-
edge neurosurgery, or more systemically.74 The for-
mer approach is more invasive, but the latter poses
problems of specificity and quantity of cells deliv-
ered. Perhaps, the most promising approaches are
those that use stem cell derivatives not only as
supportive cells in their own right but also as
BTrojan horses[ for the delivery of recombinant
proteins with known neuroprotective activity.75 Col-
lectively, these approaches certainly deserve more
development but need to surmount the hurdles of
relatively weak efficacy in preclinical models (where
evaluated), the quantity and quality of cells for
human administration, and the paucity of relevant
outcome measures during the early phases of clini-
cal trial.
Putting Stem Cell Biology to Work in a
Rehabilitation Department
How will stem cell biology and regenerative
medicine impact rehabilitation for the coming de-
cade? There are multiple challenges ahead, including
that of managing excessive expectations. The strategy
that was adopted within the Department of Rehabili-
tation and Regenerative Medicine at Columbia Uni-
versity Medical Center is a long-term one, based on
supporting cutting-edge basic research in close and
frequent contact with the physicians who understand
patients’ problems and can help to define areas that
present the most promising opportunities for future
intervention. The Columbia Stem Cell Initiative (ex-
ternal link, http://www.ColumbiaStemCell.org) has
its home within the Department of Rehabilitation
and Regenerative Medicine, while extending tomore
than 100 laboratories in all corners of the two cam-
puses. To enhance stem cell focus within the de-
partment, a Division of Regenerative Medicine was
created, which houses stem cell scientists in its own
laboratory space, and research meetings and collab-
orations involving both basic and clinical faculty
were organized.
The topic of this reviewVstem cells in the ner-
vous systemVencompasses only a fraction of the
approaches that will be needed for successful reha-
bilitation. Strategically, therefore, it will be critical to
integrate the authors’ approaches across the whole
range of pathologies encountered in rehabilitation
medicine. The authors’ plans are to do this by im-
plementing the two main research areas outlined in
this textVthe biology of stem cells and their niche
and disease modelingVand to use these as a solid
basis for new therapeutic approaches based on phar-
macologic interventions, bioengineering, and cell-
based therapy (Fig. 5).
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